Gene sequencing company Illumina Inc will pay US$7.1 billion in cash and stock to buy cancer test startup Grail Inc, the Wall Street Journal reported on Monday, citing people familiar with the matter.
Illumina to pay US$8 billion for Jeff Bezos-backed cancer testing firm Grail
